We hope you had the opportunity to visit us. Whether you are in preclinical development or commercializing your therapy, Merck provides a spectrum of solutions to the challenges in cell therapy production.
We are proud to introduce a xeno-free mesenchymal stem/stromal cell (MSC) culture medium created to support cell expansion for clinical and commercial manufacturing. Designed to perform in both planar and suspension formats, Stemline® XF MSC Medium is suited for cell therapy applications thanks to careful selection of raw materials, a sustainable supply chain, and a production process that incorporates our wealth of regulatory expertise.
Comparison of growth in microcarrier-based 3 L bioreactor format. Total cell counts on Day 8 indicate Stemline® XF MSC medium outperformed AMEM + hPL by 58.3% and a commercially available xeno-free formulation (XF-X) by 178.9%
Tri-lineage differentiation post-bioreactor expansion in Stemline® XF MSC medium. Cells maintained the ability to differentiate into osteoblasts, chondroblasts, and adipocytes. Scale bar shown in image
Available soon as a catalog product, Stemline® XF MSC Medium is formulated as a liquid basal medium and frozen supplement cocktail for ease of use. We will also offer custom packaging solutions tailored to fit your precise requirements for commercial scale cell therapy manufacturing. Keep up-to-date at merckmillipore.com/fastforward.
Working with hematopoietic or neural stem cells? Explore our media products at sigmaaldrich.com/life-science/cell-culture/stem-cells.html.
You have the need for rapid progress and a vision for making a difference in the lives of patients. With our cell therapy process development services, you have a trusted partner to drive to that goal.
Contact us or find out more at merckmillipore.com/fastforward